Veritas, a scientific leader in the field of genomics and personalized medicine, participated in this year’s Human Genome Meeting, HUGO 2024, held in Rome from April 8 to 10.

Veritas hosted a  “Meet the Expert” session  titled “Elective Genome Screening, its Role in Clinical Practice and General Health Checks,” drawing attention to the transformative potential of elective genome screening. Elective Genome Screening in clinical practice allows for the proactive identification of genetic predispositions to various conditions and is at the forefront of integrating genomic data into routine health assessments and clinical decision-making. The presentation, led by Veritas’s CTO Vicenzo Cirigliano and CMO Dr. Luis Izquierdo López, highlighted how genomic screenings can empower individuals with knowledge about their genetic health, fostering a preventive approach to care.

Moreover, Veritas, in collaboration with the Tor Vergata University, unveiled a groundbreaking abstract titled, “Polygenic Risk Score Improves the Risk Stratification and Clinical Management in Families Carrying Pathogenic Variants in Breast Cancer Related-Genes.” This work, co-authored by Professor Giuseppe Novelli, Veritas’s Chief Technical Officer Dr. Vincenzo Cirigliano, and Dr. Giuliana Longo, Scientific Advisor to Veritas’s medical-scientific team in Italy, demonstrated a significant advancement in the use of polygenic risk scores for breast cancer. The study demonstrates the enhanced ability to stratify risk and manage clinical outcomes for individuals with hereditary predispositions to breast cancer, showcasing the tangible benefits of integrating genomic insights into personalized healthcare strategies.

The collaboration between Veritas and Tor Vergata University embodies HUGO’s spirit of fostering partnerships that bridge academic research and industry innovation. By combining their expertise, the team has taken a significant step forward in utilizing genomic data to refine risk assessment models, thereby offering more nuanced and effective approaches to disease prevention and management.

HUGO 2024 also provided an ideal platform for networking and collaboration. Veritas engaged in meaningful discussions with other leaders in the field, exploring future projects and partnerships that promise to further the integration of genomics into healthcare.

Veritas’ presentations and abstract have not only highlighted the potential of genomic technologies to transform healthcare but have also set the stage for the next wave of innovations in the field.

For more information about Veritas and its services, or to learn more about the implications of their findings presented at HUGO 2024, please visit Veritas’s website.